Possible PAH Treatment, Now in Testing as Anti-Psychotic, Named Orphan Drug by FDA
News, Pulmonary Hypertension
Reviva Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to RP5063 as a potential treatment of pulmonary arterial hypertension (PAH). The product is already in clinical ... Read more